No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial
- 1Medical Department I, Rheumatology, Charité, Campus Benjamin Franklin Hospital, Berlin, Germany
- 2Medac, Wedel, Germany
- 3German Rheumatism Research Centre, Berlin, Germany
- Correspondence to:
Dr Hildrun Haibel
Medical Department I, Rheumatology, Charité, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany;
- Accepted 19 July 2006
- Published Online First 10 August 2006
Objective: To examine the potential therapeutic effect of methotrexate 20 mg given weekly as subcutaneous injections to 20 patients with ankylosing spondylitis refractory to non-steriodal antirheumatic drugs.
Patients and methods: 20 patients with ankylosing spondylitis, a mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of 5.6 (range 4–9.3) and predominantly axial manifestations were treated with weekly 15 mg methotrexate subcutaneously for 4 weeks, which was then increased to 20 mg subcutaneously for the next 12 weeks. Clinical outcome assessments included, among others, BASDAI score physical function, spinal mobility, patients’ and physicians’ global assessment (visual analogue scale), peripheral joint assessment, quality of life (Short Form 36) and C reactive protein. The primary end point of the study was a 20% improvement on the ASsessments in Ankylosing Spondylitis (ASAS 20) scale.
Results: Using an intention-to-treat analysis, ASAS 20 was achieved in only 25% of patients. An ASAS 40 response was achieved in 10% of patients, and no patient reached an ASAS 70 response or the ASAS criteria for partial remission. For the mean BASDAI score, no change was observed between baseline and week 16 (baseline 5.6 v week 16, 5.6). No improvement was observed in any of the clinical parameters or C reactive protein, except a small but non-significant decrease in the number of swollen joints.
Conclusions: In this open study, methotrexate did not show any benefit for axial manifestations in patients with active ankylosing spondylitis beyond the expected placebo response.
- DMARD, disease-modifying antirheumatic drug
- ASAS, ASsessments in Ankylosing Spondylitis
- NSAID, non-steroidal antirheumatic drug
- SpA, spondyloarthritides
Funding: This study was supported by Medac.
Competing interests: None declared.
Published Online First 10 August 2006